To improve the performance of existing non-conversational AI and ML models, LLMs that provide summaries, analysis, and recommendations based on bioproduction data and the latest findings from other researchers should be implemented as a new utility, reducing time and costs associated with updating drug production with new findings to support existing workflows shown in Figure . Multiple chained generations are likely needed in the near term due to computational resources limited by inference services or software manufacturers processing large amounts of data, limiting the utility of single prompt protocols. The future for the startup will focus on applying technical achievements shown in Table to larger and more complex problems across the field of drug discovery.